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Background: Venous thromboembolic disease (VTE) is associated with high morbi-mortality. Adherence rate to
the recommendations of antithrombotic prophylaxis guidelines (ATPG) is suboptimal. The aim of this study was to
describe the adequacy of antithrombotic prophylaxis (ATP) in hospitalized patients as the initial stage of a program
designed to improve physician adherence to –ATP recommendations in Argentina.
Methods: This study was a multicenter, cross-sectional study that included 28 Institutions throughout 5 provinces
in Argentina.
Results: 1315 patients were included, 729 (55.4%) were hospitalized for medical (clinical) reasons, and 586 (44.6%)
for surgical reasons. Adequate ATP was provided to 66.9% of the patients and was more frequent in surgical (71%)
compared to clinical (63.6%) subjects (p < 0.001). Inadequate ATP resulted from underuse in 76.6% of the patients.
Among clinical, 203 (16%) had increased bleeding risk and mechanical ATP was used infrequently.
Conclusions: The adequacy of ATP was better in low VTE risk clinical and surgical patients and high VTE risk in
orthopedic patients. There was worse adequacy in high risk patients (with active neoplasm) and in those with
pharmacological ATP contraindications, in which the use of mechanical methods was scarce. The adequacy of ATP
was greater at institutions with < 150 beds compared with larger institutions. This is the first multicentric study
reporting ATP in Argentina. Understanding local characteristics of medical performance within our territory is the
first step in order to develop measures for improving ATP in our environment.
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Deep vein thrombosisBackground
Venous thromboembolic disease (VTE) is associated with
high morbidity and mortality. Approximately 2 million
cases of deep venous thrombosis (DVT) and 200,000 deaths
from pulmonary embolism (PE) are reported annually in
the United States [1]. These numbers exceed those from
breast cancer and AIDS deaths combined [2-4]. Addition-
ally, VTE affect quality of life during both acute and chronic
phase [5,6], due to the disease itself and the bleeding risk as
a complication of anticoagulation.* Correspondence: Fernando.vazquez@hospitalitaliano.org.ar
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unless otherwise stated.Despite its health impact [1,7] and the availability of
evidence-based antithrombotic guidelines (ATPG) on
prophylaxis [8-10], the adherence rate to such recom-
mendations has been reported in several studies as being
suboptimal [11,12].
Although there are reports on the adequacy of anti-
thrombotic prophylaxis (ATP) in different countries,
in Argentina there are only two reports in two local
hospitals that describe ATPG adherence [13,14]. This
paper describes the adequacy of ATP guideline compliance
in hospitalized patients as the initial stage of a program
designed to improve physician adherence to VTE prophy-
laxis recommendations.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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To determine the proportion of patients at risk of VTE
who receive appropriate, recommended ATP.
Secondary objective
To evaluate the association between the different charac-
teristics within participating institutions and adherence





The survey was conducted at 28 institutions located in 5
provinces of Argentina. The institutions were classified
according to the presence of training medical residents
and categorized according to the number of beds (less
or more than 150 beds). The proportion of admitted
patients with elevated risk (APER) of VTE (> or ≤ 70%) in
each Institution was also classified. The present study
involves several Institutions with different case mix of
patients. Data of previously published studies from Latin
america have shown that 60 to 80% of hospitalized
patients belong to moderate to high risk of VTE categories
[14,15].
Subsequently, the association between these variables
and the adequacy of ATP prescription was assessed.
Each institution had one local coordinator who selected
a group who in turn conducted the local survey. To
ensure homogeneity of the data collection, all of the
participating investigators received the same training.
To avoid prescribing behavioral changes for VTE
prophylaxis, the attending physicians were blinded to
the purpose or timing of the survey.
A unique form was designed and used by all of the
participating Institutions. This form allowed the identifi-
cation of variables that determined the risk group for
each patient as well as the type of prophylaxis received.
For the elaboration of the form and to determine the ad-
equacy of the prophylaxis according to the risk of VTE,
we used as a frame of reference the American College of
Chest Physician (ACCP) guide, which was published in
2008 [9].
The survey was performed during a random day in
each institution between June 2009 and October 2011,
using a cross-sectional model of all hospitalized patients
who had met defined inclusion and exclusion criteria.
At the time of the analysis, the type of hospitalization
(medical or surgical), the presence or absence of risk
factors, the reason for hospitalization or surgery, the pres-
ence of increased bleeding risk and the type of prescribed
prophylaxis were considered. For clinical patients, the age,
reason for admission and presence of VTE risk factorswere considered. The following factors were considered in
surgical patients: age, surgery type (programmed vs. emer-
gency), duration, and whether it was related to a neoplasm
or not.
Definitions: for the definition of adequate prophylaxis all
Institutions created a protocol to guide the prescription of
VTE prophylaxis, based on the ACCP guidelines [9,16].
Adequate prophylaxis was considered when 1) the patient
had increased VTE risk, low bleeding risk and received
pharmacological thromboprophylaxis in adequate doses; 2)
the patient had low VTE risk, no indication for ATP, and
did not receive prophylaxis and 3) patients had increased
VTE and bleeding risk did not receive any pharmaco-
logical thromboprophylaxis but received a mechanical
one. Within the group of patients with increased VTE
risk, there was another subgroup considered as very high
risk: patients with active cancer, history of VTE or major
orthopedic surgery.
In patients who received inadequate prophylaxis, we dif-
ferentiate two groups: excessive inadequate prophylaxis,
when the patient received pharmacological ATP without
clinical indication, or when the administered dose was
higher than recommended. On the other side, insufficient
inadequate prophylaxis when the patient had an increased
VTE risk but received no prescription for prophylaxis or
the prescribed dose was less than recommended [9,16].
Contraindications for pharmacological prophylaxis: plate-
lets count < 50.000/ml, active bleeding, recent (in the last
7 days) major bleeding, severe renal failure (< 30 ml/min
creatinine clearance), coagulopathy (including disseminated
intravascular coagulation, coagulopathy related with sepsis,
liver failure, hemophilia, von Willebrand disease, any severe
laboratory alteration in coagulation test), active peptic ulcer,
contraindication related with invasive procedures.
The data was obtained from medical records and pa-
tient prescriptions without direct contact between the
investigator and the patient or the treating physician.Inclusion criteria
Hospitalized patients aged 21 years or older.Exclusion criteria
Pregnancy, postpartum within the last month, patients
participating in another clinical study, patients receiving
anticoagulants for any reason, patients hospitalized be-
cause of DVT or PE and those hospitalized in intensive
care units.
Each form was recorded in Access® for future analysis.
The study was performed in compliance with the Helsinki
Declaration and was approved by the Ethics Committee of
each Institution. An oral informed consent was obtained
from each patient, as required in Argentina for observa-
tional designs.
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All of the data analyses were performed with IBM SPSS
software, version 19 (SPSS, Chicago, Illinois). Continu-
ous variables are described as mean with their standard
deviations, and categorical variables are described as pro-
portions with 95% CI. The means were compared with a
t-test, and the proportions were compared with χ2 or
Fisher’s exact tests. A statistical significance was consid-
ered when p < 0.05. To assess factors associated with ad-
equate prophylaxis a multiple logistic regression was used.
Variables that were statistically significant in univariate
analysis and those not significant but with clinical rele-
vance were included in it. Results are expressed as OR
and 95% CI for each explanatory variable. The goodness
of fit of the model was assessed with Hosmer-Lemeshow.
Results
Of 1344 patients recorded, 29 (2.2%) were excluded
because of missing data, and 1315 were included in the
analysis. There were 729 (55.4%, CI 95% 53–58) patients
hospitalized for clinical reasons and 586 (44.6%, CI 95%
42–47) hospitalized for surgical reasons, of whom, 182
(31.1%) were orthopedic surgeries and 404 (68.9%) were
non orthopedic (Figure 1).
Mean age was 61.5 (SD 18.7) years, and 677 (51.5%, CI
95% 49–54) patients were male. Baseline characteristics
and their primary risk factors (RFs) for VTE are shown
in Table 1.Figure 1 Flowchart of patients evaluated in the study.Five hundred eleven (38.9%, CI 95% 36–41) patients had
one RF for VTE, 269 (20.5%, CI 95% 18–23) had 2 RFs,
149 (11.3%, CI 95% 9.6-1.3) had 3 or more RFs and no
RFs were found in 386 (29.4%, CI 95% 9.6-1.3) patients.
A head-to-head comparison of the clinical and surgical
patients showed that clinical patients were older, exhib-
ited more prolonged immobility and/or paralysis of one
or more extremities and suffered from congestive heart
failure, chronic obstructive pulmonary disease and mye-
loproliferative syndromes. The coexistence of 2 or more
RFs for VTE was more common in the clinical than in
the surgical group (78% vs. 61%). The presence of an
active neoplasm was common in both groups; with a
prevalence of 21.8% (CI 95% 19–25) in clinical and 19.3%
(CI 95% 16–22) in surgical patients (Table 1).
Considering the entire analyzed population, 880 (66.9%,
CI 95% 64–69) patients received adequate ATP. However,
ATP was more appropriately indicated in surgical patients,
416 (71%, CI 95% 67–75) than in clinical patients, 464
(63.6%, CI 95% 60–67), (p <0.001).
Among the 435 (33.1%, CI 95% 31–36) cases of inad-
equate ATP, both in the global cohort and in each separate
group (clinical and surgical), ATP was insufficient in 76.6%
(CI 95%.73-81) and excessive in 23.4% (CI 95% 20–27).
Low-molecular weight heparins (LMWH) were the most
frequent pharmacological ATP drug used, in 569/873
(65.1%, CI 95% 62–68) of the total cases, similar among
clinical and surgical patients.
Table 1 Baseline characteristics of the population
Population Total n = 1315 Clinical n = 729 Surgical n = 586 p -value
Age (years)* 61.5 (18.7%) 64.5 (18.7%) 57.8 (17.9%) < 0.001
Male gender N (%)** 677 (51.5%, 49-54) 384 (52.7%) 49-56) 293 (50.0%) (46-54) NS
Risk factors n (%)
Prolonged rest or lower limb paralysis 483 (36.7%) (34-39) 330 (45.3%) 42-49 153 (26.1%) (23-30) < 0.001
Active cancer and/or chemotherapy treatment 272 (20.7%) (18-23) 159 (21.8%) (19-25) 113 (19.3%) 16-22 NS
Overweight (BMI > 25) 267 (20.3%) (18-22) 330 (45.3%) (17-23) 123 (21%) (18-24) NS
Varicose veins or chronic venous insufficiency 112 (8.5%) (7-.1) 68 (9.3%) (7-11) 44 (7.5%) (5-10) NS
Heart failure 111 (8.4%) (7-10) 85 (11.7%) (9-14) 26 (4.4%) (3-6) < 0.001
Central venous catheter 116 (8.4%) (7-10) 61 (8.4%) (63-10) 55 (9.4%) (7-12) NS
Chronic obstructive pulmonary disease 78 (5.9%) (5-7) 61 (8.4%) (6-10) 17 (2.9%) (2-4) <0.001
History of DVT/PE 27 (2.1%) (1-3) 21 (2.9%) (2-4) 6 (1.0%) (2-2) 0.018
Myeloproliferative syndrome 18 (1.4%) 7-2) 17 (2.3%) (1-3) 1 (0.2%) (2-5) < 0.001
Inflammatory disease 15 (1.1%) (0.57-1.7) 11 (1.5%) (1-2) 4 (0.7%) (0.1-1.3) NS
Estrogen therapy 14 (1.1%) 0.5-1.6 7 (1%) (0.2-2) 7 (1.2%) (0.32) NS
Nephrotic syndrome 12 (0.9%) (0.4-1.4) 10 (1.4%) (1-2) 2 (0.3%) (0.1-0.8) NS
Thrombophilia 5 (0.4%) 0.05-0.7 3 (0.4%) (0.1-0.9) 2 (0.3%) (0.13-0.8) NS
*Expressed as the mean and standard deviation (SD).
**Expressed as proportions and the confidence interval.
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commonly used ATP strategy in 163/873 (18.7%, CI 95%
16–20) patients. UFH was not more significantly used in
clinical 107 (14.7%, CI 95% 12–17) than in surgical
patients 56 (9.6%, CI 95% 7–12). New oral anticoagulants
(NOA) were prescribed less commonly.
One or more bleeding risk factors were identified in
213 (16.2%) cases, and this issue occurred more com-
monly in clinical patients. Bleeding risk factors included
severe renal failure in 71 (33.3%) patients, active bleed-
ing in 67 (31.5%) patients and thrombocytopenia in 57
(26.8%) patients. Thrombocytopenia was the only factor
more commonly found in clinical patients (30.6% vs.
11.6%, p = 0.015).
Infrequent bleeding risk factors were coagulation dis-
orders (9.9%) central nervous system hemorrhage (7%)
and hepatic insufficiency (5.2%). Of the 213 patients
with bleeding risk factors, ATP was adequate in 107
(50.2%). One hundred and sixty patients showed abso-
lute contraindications for pharmacological ATP; and
only 23 (13.8%) received adequate mechanical ATP. A
hundred and thirty cases had a high risk for VTE in
this group but the ATP prescribed was adequate in
only 42 (32.3%) patients.
Mechanical ATP measures were rarely used. Graded
compression stockings (GCS), were indicated in 70 (5.3%,
CI 95% 4–7) patients, and intermittent pneumatic
compression in 13 (1%, CI 95% 0.5-2). GCS were used
more commonly in the clinical group (7.1% vs. 2.4%,
p < 0.001).Early ambulation was indicated in 229 (17.5%, CI 95%
15–19) cases and was significantly more common in the
surgical (25.6%, CI 95% 22–29) than in the clinical group
(11%, CI 95% 9–13, p < 0.001).
Clinical patients
Of the 729 patients with clinical conditions, 430 (59%, CI
95% 55–63) exhibited total immobility or had only bath-
room privileges while hospitalized and were associated with
at least one other RF for VTE. The three leading causes of
hospitalization were acute infection (39.3%, CI 95% 35–44),
cancer complications (30.7%, CI 95% 26–35) and stroke
(22.3%, CI 95% 18–26).
Among the patients hospitalized for clinical reasons, 620
(85%) should have received ATP. However, ATP was
adequate in only 464 patients (63.6%, CI 95% 60–67) and
inadequate in 265 (36.4%, CI 95% 33–40). In 203 cases
(76.6%, CI 95% 72–82) the main reason for inadequacy was
underuse and in 62 (23.46%, CI 95% 18–28) was excessive
use. In the clinical group 129 (20.8%) had contraindications
for receiving pharmacological ATP. No need to receive ATP
was present in 109 cases (15%) of low VTE risk; this group
was adequately treated without ATP in 79 cases (72.5%),
but ATP in excess was prescribed in 30 cases (17.5%).
Among the patients meeting criteria for receiving ATP,
385/620 (62.1%) cases received adequate ATP and, among
those without any criteria for receiving ATP (low risk of
VTE), ATP was prescribed adequately in 79/105 (72.5%)
cases. The difference between the two groups was statisti-
cally significant (p < 0.001).
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Of the 586 patients with surgical conditions, 384 (65.4%,
CI 95% 62–69) had undergone an elective surgery, 420
(71.6%, CI 95% 68–75) had undergone procedures last-
ing more than 45 minutes, 31% had undergone ortho-
pedic surgery, and surgery was indicated in 95 (16%, CI
95% 13–19) patients because of oncologic conditions.
The types of surgical procedures are shown in Figures 2
and 3. The different types of surgeries surveyed are out-
lined in Figures 2 and 3.
Subgroup of orthopedic surgery
The 182 patients with orthopedic surgical conditions were
classified into high or low risk for thrombosis; in the high
risk group (hip or knee prosthesis and hip fracture) 57/61
(93.4%, CI 95% 87–99) received adequate ATP. In the
remaining 121 with low to moderate VTE risk prophylaxis
was adequate in 90 (74.4%, CI 95% 67–82) cases.
Subgroup of general surgery
In this group of 404 patients, 238 (59%, CI 95% 50–59)
had high-risk of VTE, 39 (9.6%, CI 95% 7–13) had
moderate-risk and 127 (31.4%, CI 95% 31–40) had low-
risk. Overall, 267 (66.1%) patients received adequate ATP.
In 120 cases, (83.6%) ATP was insufficient and this situ-
ation was significantly more common in the VTE high risk
group, 103 (43.3% CI 95% 37–50) and 16 with moderate
risk (40.9%, CI 95% 26–55) patients (Table 2).
Characteristics of the participating institutions
There was no association between the presence of a resi-
dency program (p 0.27), nor the percentage of patients
at high VTE risk (p 0.057) with the appropriateness ofFigure 2 Types of orthopedic surgical procedures.the indications of prophylaxis; however, institutions with
fewer beds (p 0.027) had higher frequency of appropriate
prophylaxis.
Table 3 shows the variables assessed in the multiple lo-
gistic regression model. Institutions with more than 150
beds, patients with active cancer and those with contrain-
dicated anticoagulation were associated with inadequate
ATP, while major orthopedic surgery was associated with
better adequacy of ATP.
Discussion
This study shows that approximately 70% of the patients
admitted to general hospitals in different provinces in
Argentina presented risk factors for VTE and, therefore,
should have received antithrombotic prophylaxis.
One-third of the patients showed several combined risk
factors for VTE; prolonged bed rest, cancer and obesity
were the three most commonly observed, consistent with
the report of Cohen et al. [11].
The primary causes for hospitalization due to medical
conditions included respiratory conditions, infections, ma-
lignancy and acute neurological conditions, consistent
with previous reports [14]. The most frequent surgeries
were orthopedic and both conventional and laparoscopic
abdominal surgery, followed by urological surgery.
Similar to what Gladding et al. [17] found, the propor-
tion of patients with medical conditions and with increased
risk for VTE, was greater than the proportion of surgical
patients with increased risk (84.2% vs. 67.6%) (p < 0.001).
Adequacy of ATP was higher in the low risk medical
group of patients.
The use of ATP was adequate in 66.9% of the total
patients surveyed and was more common among the
Figure 3 Non-orthopedic surgical procedures.
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orthopedic surgeries) than among those hospitalized with
medical conditions. If non-surgical patients are taken into
account, the adequacy of ATP was higher than previously
reported [18,19].
In patients undergoing orthopedic surgery, ATP was
more appropriate in patients at high risk for VTE, unlike
general surgical patients, in whom the adequacy of ATP
was higher in patients categorized as low risk.
The better compliance in the surgical group in com-
parison with those in the medical group may be related
to the fact that it is simpler to categorize the risk for
VTE in patients with surgical conditions (particularly in
major orthopedic surgeries) than in those with clinical
conditions and that the benefits of prophylaxis in patients
with clinical conditions have been shown more recently
than the benefits for surgical conditions.
In this study the adequate thromboprophylaxis was
higher than the average reported in the literature [11,12].
It is important to emphasize that the result of the inad-
equacy in the administration of pharmacological prophy-
laxis has two consequences: in the case of underutilization,
the risk of VTE is increased; and when used in excess, can
increase the risk of bleeding. Regarding the two previous
studies performed in Argentina [13,14], adherence rates of
ATP in this study were lower. Previous studies wereTable 2 Prophylaxis in non-orthopedic patients according to
Risk group Patients
(N = 404) 100%
Adequate
(N = 267) 66.1%
High 238 (59%) (50-59) 129 (54.2%) (52-65)
Moderate 39 (9.6%) (7-13) 23 (59.1%) (4.5-7.4)
Low 127 (31.4%) (31-40) 115 (90.5%) (83-93)
p < 0.001.conducted in a single center, with fewer beds, facilitating a
tighter control of the prescriptions. Moreover, in one
study, physicians were not unblinded to the survey, and
this could be interpreted as a bias, to proper indication for
thromboprophylaxis (13).
At least one factor that increased bleeding risk was
observed in 16.2% of the patients surveyed which was
greater than reported by Vallano et al. [19]; most of these
patients had been hospitalized for clinical conditions.
One-third had an increased bleeding risk because of se-
vere renal failure with a creatinine clearance < 30 mL/min.
The remaining patients had formal contraindications for
receiving pharmacological antithrombotic prophylaxis.
The number of patients with contraindications for ATP
was similar to previous reports [11,12,14].
There are two situations in which there is a troubling
lack of adherence to ATP.
First, the antithrombotic prophylaxis was adequate in
only half of the patients with an increased risk of VTE
and absolute contraindication for pharmacological ATP.
In this regard, it is interesting to note the scarce use of
mechanical prophylaxis in this group of patients. Sec-
ondly, in surgical patients being operated for cancer
(16.5%), who were at very high thrombotic risk only
55.6% of these patients received adequate ATP. These
two situations are probably the ones generating morethe risk group
Inadequate excessive
(N = 17) 4%
Inadequate insufficient
(N = 120) 29.7%
6 (2.5%) (0.5-5) 103 (43.3)
0 (0) 16 (40.9)
11 (8.6%) (6-16) 1 (0.8)
Table 3 Variables evaluated with multiple logistic
regression model for appropriate prophylaxis
Variable OR CI 95%
Age 0.99 0.99-1.01
Length of stay 1.01 0.783-1.31
History of VTD 1.25 0.52-3.03
Active cancer 0.63 0.47-0.83
Major orthopedic surgery 5.80 2.05-16.43
APER (>70%) 1.15 0.89-1.49
Number of beds (>150) 0.74 0.57-0.95
Residency 1.20 0.88-1.63
Contraindication for pharmacological prophylaxis 0.34 0.24-0.47
OR: odds ratio; CI 95%: confidence interval; VTD: venous thromboembolic
disease; APER: proportion of Admitted Patients with Elevated Risk > 70%.
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in ATP in these subgroups.
The analysis of the causes for inadequate ATP revealed
that it was primarily caused by overuse in patients within
the low-risk category, while underuse was observed in
both high-risk and moderate-risk patients. Across all insti-
tutions, the most common type of pharmacological ATP
used was LMWH followed by UFH.
Of note is that smaller institutions prescribe ATP
more adequately reflecting the greater feasibility of ap-
propriate control of thromboprophylaxis prescriptions
and with greater feedback when inadequate ATP pre-
scription is made.
VTE has been identified as the number one cause of
preventable death among hospitalized patients, and one
of the most important causes is contrast between our
in-depth knowledge of how to prevent VTE and our
lackadaisical implementation of prophylactic measures,
which is unacceptable. In 2008, Medicare declared the
occurrence of VTE after total knee or hip replacement
to be a “never event.” This means that hospitals will
have to pay for the extra costs of treating postoperative
DVT or PE following knee or hip replacement [20].
Regarding compliance with the indications for ATP
according to the recommendations in different patient
groups, we believe that local awareness in our country is
of utmost importance when interventional measures
begin; the objective should be to improve patient risk
stratification, thereby optimizing the appropriate indica-
tion for ATP.
Once we identified thromboprophylaxis to be subopti-
mal, we consider it necessary to implement multiple
strategies (continuing medical education that involve all
health personnel, monitoring and feedback, electronic
support systems for decision making [21-23], etc.) to
improve adherence to the prophylaxis guidelines in
Argentina, with the objective of enhancing the safety of
hospitalized patients, especially in the high risk group.Limitations: Because this is a cross-sectional study
conducted at different times in various institutions, some
may have had more time than others to become familiar
with the guidelines and recommendations that could
influence the appropriateness of their prescriptions. This
study also has strengths: it was performed by similarly
trained physicians to collect data, and these were analyzed
by the same person (EL) to achieve uniformity in the
processing and interpretation between the different insti-
tutions. The study demonstrates the everyday practice in a
large sample of the Argentine health system. Considering
that no action has been taken yet for improvement, values
of adequacy of prophylaxis are above the average of other
countries in Latin America.
Conclusion: This is the first multicenter cross-sectional
study performed in different provinces of Argentina to
asses ATP guideline compliance. Although this study
shows that adequate thromboprophylaxis was higher than
in the average reported in the literature, we believe that
implement multiple strategies to improve adherence to
prophylaxis guidelines is necessary in Argentina, with the
objective of enhancing the safety of hospitalized patients.
The two groups with worse adequacy were those with
contraindication for pharmacological prophylaxis, in which
no mechanical measures were used and patients undergo-
ing surgery for cancer. In this high risk groups we need to
focus especial attention to improve thromboprophylaxis.
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